A phase I clinical trial evaluating the tolerability and pharmacokinetics of TQB2916 injection in subjects with advanced malignant tumors
Latest Information Update: 22 Oct 2024
At a glance
- Drugs BSI 038 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Zhengda Tianqing Pharmaceutical Group Co., Ltd.
Most Recent Events
- 11 May 2023 New trial record